Spotlight On... Docs take aim at Novartis' 'horrifying' Entresto ad; U.K. cost gatekeepers shun Sanofi's PCSK9 drug but back Amgen's; BMS wins hep C label expansion for Daklinza; and more...

It's not often that a disease-awareness campaign makes unwanted waves. But Novartis' ($NVS) recently launched heart failure push is doing just that--literally and figuratively. More from FiercePharma

> U.K. cost watchdogs have backed Amgen's ($AMGN) PCSK9 contender, Repatha, but given Sanofi's ($SNY)--dubbed Praluent--a thumbs down. Report

> The FDA has green-lighted Bristol-Myers Squibb's ($BMY) Daklinza for more hard-to-treat hep C patients. Release

> Amid backlash for soaring drug prices, industry trade group PhRMA says it intends to spend several millions this year--10% more than in 2015--on digital, radio and print ads that highlight the industry's role in developing new treatments and advancing science. Report

> Cigna announced that it has entered into an outcomes-based contract with Novartis ($NVS) over heart-failure newcomer Entresto. More

Suggested Articles

A phase 1 study of the Inlyta-Keytruda regimen, which bears a first-line nod for kidney cancer, got the ax along with several Bavencio tests.

NICE rejected Spravato over cost concerns and a lack of head-to-head clinical data against other NICE-recommended alternatives.

Eli Lilly and Incyte are investing heavily in JAK inhibitor Olumiant's chances in atopic dermatitis, but does it stand a chance against Dupixent?